Treatment of HIV-Related Primary Central Nervous System Lymphoma (HIV-PCNSL): A Phase II Trial With Neoadjuvant Chemotherapy (High-Dose Methotrexate (MTX) Plus High-Dose Zidovudine) and Radiotherapy
- Determine the efficacy of neoadjuvant chemotherapy and radiation therapy in the
treatment of HIV-related primary CNS lymphoma patients.
- Evaluate the toxicity and overall survival of these patients.
OUTLINE: Patients receive chemotherapy consisting of high-dose methotrexate IV administered
on day 1 and high-dose zidovudine IV administered on days 1-3 every 2 weeks. Patients
receive 3 courses of therapy. Following chemotherapy, patients receive radiation therapy to
the lesion site daily.
Patients are followed every 3 months for 1 year and then every 6 months thereafter.
PROJECTED ACCRUAL: This study will accrue 14 patients.
Primary Purpose: Treatment
Umberto Tirelli, MD
Centro di Riferimento Oncologico - Aviano
United States: Federal Government